


## Ivonescimab outperforms pembrolizumab in study for first-line treatment of PD-L1-positive advanced NSCLC: Clinical trial

September 8 2024





Credit: Pixabay/CC0 Public Domain

Data from a Phase 3 study has revealed that ivonescimab demonstrates a statistically significant and clinically meaningful improvement in progression-free survival compared to pembrolizumab for patients with PD-L1-positive advanced non-small cell lung cancer. The results were presented today at the <u>International Association for the Study of Lung Cancer (IASLC) 2024 World Conference on Lung Cancer</u>.

The HARMONi-2 study randomized 398 patients from 55 centers in China to receive either ivonescimab (20 mg/kg) or pembrolizumab (200 mg) every three weeks. To be eligible for the trial, patients had to have untreated locally advanced or metastatic NSCLC, ECOG PS 0-1, PD-L1 positive (TPS ≥1%) but negative EGFR mutations or ALK rearrangements.

At the planned interim analysis, ivonescimab demonstrated a median PFS of 11.14 months, significantly longer than the 5.82 months observed with pembrolizumab. This represents a 49% reduction in the risk of progression or death (stratified hazard ratio [HR], 0.51; 95% CI, 0.38 to 0.69; p

Citation: Ivonescimab outperforms pembrolizumab in study for first-line treatment of PD-L1-positive advanced NSCLC: Clinical trial (2024, September 8) retrieved 8 September 2024 from

https://medicalxpress.com/news/2024-09-ivonescimab-outperforms-pembrolizumab-line-treatment.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private



study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.